Generic Name and Formulations:
Ceftaroline fosamil 400mg, 600mg; per vial; pwd for IV infusion after reconstitution and dilution.
Indications for TEFLARO:
Susceptible bacterial community-acquired pneumonia and acute skin and skin structure infections.
≥18yrs: Give by IV infusion over 5–60mins. Treat skin and skin structure for 5–14 days; treat pneumonia for 5–7days. CrCl >50mL/min: 600mg every 12hrs. Renal impairment (CrCl >30–≤50mL/min): 400mg every 12hrs; (CrCl ≥15–≤30mL/min): 300mg every 12hrs; ESRD (including hemodialysis): 200mg every 12hrs (dose after dialysis on dialysis days).
<2mos: not established. Give by IV infusion over 5–60mins. 2mos–<2yrs: 8mg/kg every 8hrs. ≥2yrs–<18yrs (≤33kg): 12mg/kg every 8hrs; (>33kg): 400mg every 8hrs or 600mg every 12hrs. All: treat for 5–14 days.
Penicillin or other beta-lactam allergy. GI disease (esp. colitis). Monitor for hemolytic anemia. Pregnancy. Nursing mothers.
May cause false (+) direct Coomb's test.
Diarrhea, nausea, vomiting, pyrexia, rash; pseudomembranous colitis, superinfection.
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes